000079132 001__ 79132 000079132 005__ 20200716101528.0 000079132 0248_ $$2sideral$$a111089 000079132 037__ $$aART-2019-111089 000079132 041__ $$aeng 000079132 100__ $$aCantón, R. 000079132 245__ $$aMonitoring the antimicrobial susceptibility of Gramnegative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017) 000079132 260__ $$c2019 000079132 5060_ $$aAccess copy available to the general public$$fUnrestricted 000079132 5203_ $$aOBJECTIVE: Continuous antimicrobial resistance surveillance is recommended by Public Health authorities. We up-dated data from the SMART (Study for Monitoring Antimicrobial Resistance Trends) surveillance study in Spain. METHODS: The antimicrobial susceptibility data and extended-spectrum beta-lactamase (ESBL) production in isolates recovered from intra-abdominal (IAI) (n=1,429) and urinary tract (UTI) (n=937) infections during the 2016- 2017 SMART study in 10 Spanish hospitals were analysed. RESULTS: Escherichia coli was the most frequently microorganism isolated (48.3% and 53.7%) followed by Klebsiella spp. (11.5% and 21.9%) in IAIs and UTIs, respectively. Figures for Pseudomonas aeruginosa were 9.0% and 6.1%, being more frequently recovered from patients with nosocomial infections. Overall, 9.9% (IAI) and 14.0% (UTI) of E. coli, Klebsiella spp. and Proteus mirabilis isolates were ESBL-producers, being Klebsiella pneumoniae (34.5%) from UTI of nosocomial origin the most frequent. ESBL-producers were higher in patients >60 years in both IAIs and UTIs. As in previous years, amikacin (96.3%-100% susceptibility), ertapenem (84.2%-100%) and imipenem (70.3%- 100%) were the most active antimicrobials tested among Enterobacterales species. The activity of amoxicillin-clavulanic, piperacillin-tazobactam, and ciprofloxacin susceptibility was lower, particularly among ESBL-producers. Ertapenem susceptibility (88.9%-100%) was retained in ESBL-E. coli isolates that were resistant to these antimicrobials but decreased (28.6%-100%) in similar isolates of K. pneumoniae. CONCLUSIONS: Continuous antimicrobial resistance surveillance from the SMART study reveals overall maintenance of ESBL-producers in Spain, although with higher presence in isolates from UTIs than from IAIs. Moreover, ertapenem activity was high in E. coli irrespective of ESBL production but decreased in K. pneumoniae, particularly among ESBL-producers. 000079132 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/ 000079132 590__ $$a1.132$$b2019 000079132 591__ $$aPHARMACOLOGY & PHARMACY$$b246 / 270 = 0.911$$c2019$$dQ4$$eT3 000079132 591__ $$aMICROBIOLOGY$$b121 / 134 = 0.903$$c2019$$dQ4$$eT3 000079132 592__ $$a0.287$$b2019 000079132 593__ $$aMedicine (miscellaneous)$$c2019$$dQ3 000079132 593__ $$aPharmacology$$c2019$$dQ3 000079132 593__ $$aMicrobiology (medical)$$c2019$$dQ3 000079132 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000079132 700__ $$aLoza, E. 000079132 700__ $$aAznar, J. 000079132 700__ $$0(orcid)0000-0002-2519-701X$$aCastillo, F.J.$$uUniversidad de Zaragoza 000079132 700__ $$aCercenado, E. 000079132 700__ $$aFraile-Ribot, P.A. 000079132 700__ $$aGonzález-Romo, F. 000079132 700__ $$aLópez-Hontangas, J.L. 000079132 700__ $$aRodríguez-Lozano, J. 000079132 700__ $$aSuárez-Barrenechea, A.I. 000079132 700__ $$aTubau, F. 000079132 700__ $$aDíaz-Regañón, J. 000079132 700__ $$aLópez-Mendoza, D. 000079132 700__ $$0(orcid)0000-0002-9742-1463$$aSeral, C.$$uUniversidad de Zaragoza 000079132 700__ $$aCalvo, J. 000079132 700__ $$aDomínguez, M.A. 000079132 700__ $$aPérez Sáenz, J.L. 000079132 700__ $$aOliver, A. 000079132 700__ $$aGarcía-Castillo, M. 000079132 700__ $$aPrieto, J. 000079132 700__ $$aAznar, J. 000079132 700__ $$aRodríguez-Rey, A. 000079132 700__ $$aPascual, A. 000079132 7102_ $$11008$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Microbiología 000079132 773__ $$g32, 2 (2019), 145-155$$pRev. esp. quimioter.$$tRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia$$x1988-9518 000079132 85641 $$uhttps://seq.es/wp-content/uploads/2019/02/canton13feb2019.pdf$$zTexto completo de la revista 000079132 8564_ $$s706814$$uhttps://zaguan.unizar.es/record/79132/files/texto_completo.pdf$$yVersión publicada 000079132 8564_ $$s105657$$uhttps://zaguan.unizar.es/record/79132/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000079132 909CO $$ooai:zaguan.unizar.es:79132$$particulos$$pdriver 000079132 951__ $$a2020-07-16-09:32:26 000079132 980__ $$aARTICLE